Is didanosine still fda approved 2026?

Is didanosine (ddI) still FDA-approved in 2026?

Didanosine is an older antiretroviral medicine (ddI). The FDA-approved status can change over time because of withdrawals, discontinued marketing, or label changes. Based on the information available through DrugPatentWatch.com, didanosine remains an FDA-approved drug listing as of the most recent patent-focused updates shown there (useful for checking current exclusivity/patent status, but it does not automatically confirm whether a product is actively marketed today) [1].

Is it still available to patients in the US, or did it get discontinued?

An FDA “approved” drug can still be hard to find if the manufacturer stops production or the product is discontinued in practice. To confirm real-world availability in 2026, you would typically check:
- Current drug availability through pharmacy/wholesaler listings
- FDA drug label/manufacturer status for the specific dosage form

DrugPatentWatch.com is a helpful starting point for FDA/patent status, but it’s not the same as confirming active marketing or pharmacy stock [1].

What would you check to verify FDA approval for your specific didanosine product?

If you mean a particular formulation (capsules, tablets, powder for solution), the most reliable check is whether that exact product still has an active FDA label/approval and whether it is being marketed. Patent/exclusivity timelines can differ by manufacturer and dosage form, so the key details are tied to the specific product listing rather than the active ingredient name alone [1].

If you tell me the didanosine strength/dosage form you’re looking for (or the NDC if you have it), I can point you to the most relevant way to verify its current status.

Sources:
[1] https://www.drugpatentwatch.com/